Refine your search

Search Results

Here are the studies that match your search criteria. If you are interested in participating, please reach out to the contact listed for the study. If no contact is listed, contact us and we'll help you find the right person.

410 Study Matches

An Observational, Non-Interventional Study of Patients with Hereditary Angioedema in the United States and Canada (EMPOWER study)

Evaluate real-world effectiveness of drug in patients with hereditary angioedema (HAE). Patient reported attack diaries and patient-reported outcomes (PROs) as well as physician assessments at visits will be used to describe HAE attack rates, treatment patterns, healthcare utilization and patient quality of life.
Joshua Adams at jadams4@pennstatehealth.psu.edu or 717-531-4513
All
All
This study is NOT accepting healthy volunteers
NCT03845400
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Voluntarily able to provide consent
Diagnosis of HAE Type I or Type II
Able to use a mobile device for data collection in the study
Exclusion Criteria:
Participation in any interventional clinical trial at the time of enrollment
Unable to provide consent
Investigator believes patient is not a suitable candidate for the study
Infectious Diseases & Immune System
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

CLadribine tablets: Observational evaluation of effectIveness and patient-reported outcomes (PROs) in suboptimally Controlled patients previously taKing injectable disease-modifying drugs (DMDs) for relapsing forms of Multiple Sclerosis (RMS) (CLICK-MS)

The purpose of this study is to understand how well multiple sclerosis (MS) patients respond to a drug to help with relapsing MS (RMS), This is an oral drug called Cladribine. An observational study is research that aims to collect data over time on how a certain treatment is used and its effects, without any change to your normal care. This means that routine clinical practice is followed. Any treatment given follows your normal routine and is decided by you and your doctor. This study will not alter or interfere with the normal care you receive in any way.
All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT03933215
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Have diagnosis of relapsing multiple sclerosis (RMS)
Have experienced suboptimal response (lack of effectiveness, intolerability, poor adherence) to injectable disease-modifying drug treatment
Exclusion Criteria:
Patients who do not have relapsing multiple sclerosis (RMS)
Patients who are doing well on injectable disease-modifying drugs
Patients who have previously been treated with cladribine in any form
Pregnant or breastfeeding women, women who plan to become pregnant or men whose partner plans to become pregnant during study
Neurology
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

Associations of dietary preferences with management of HS symptoms

We will be examining the diets of people with hidradenitis suppurativa to see if they consume different amounts of foods like dairy, tomatoes, or gluten.
Melissa Butt at mbutt1@pennstatehealth.psu.edu
All
18 year(s) or older
This study is NOT accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
People who have a history of hidradenitis suppurativa
Seen at Penn State Health within the past year
18 years of age or older
Can read/write in English
Have access to the internet
Exclusion Criteria:
Those who do not meet inclusion criteria
Skin Conditions, Food & Nutrition
  Email this study information to me
  Contact the study team

M16-824 A phase 3 Study to Evaluate the Safety and Efficacy of Elagolix for the Management of Heavy Menstrual Bleeding Associated with Uterine Fibroids in Premenopausal Women.

The purpose of this study is to determine the safety and effectiveness of elagolix 150 mg once daily and how this dosage of elagolix works when compared to placebo in reducing heavy menstrual bleeding, the major symptom of uterine fibroids. Elagolix is an investigational drug which suppresses the production of estrogen depending on the dose. Because Elagolix can reduce the estrogen below the normal level, it is being tested for the treatment of symptoms of endometriosis and uterine fibroids, two conditions are that hormone-dependent. Participation in this study will last approximately up to 22 months and include approximately 10-12 study visits to the research center and approximately 4 visits that will be conducted over the phone.
Erin Hammett at ehammett@pennstatehealth.psu.edu or 717-531-1510
Female
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT03886220
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Premenopausal women, 18
•51 years old
Diagnosis of uterine fibroids with heavy menstrual bleeding
Regular menstrual cycles between 24
•38 days in length
Must agree to use at least 2 forms of non-hormonal contraception throughout the study period.
Exclusion Criteria:
No osteoporosis or other metabolic bone disease
No history of suicide ideation or attempts
Not currently pregnant, breastfeeding or planning to become pregnant until study completion
Women's Health
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

PSCI-18-052 A Phase II Study to Evaluate the Response and Tolerability of Verzenio (Abemaciclib) in Patients with Advanced Biliary Tract Carcinoma who have Failed Prior Chemotherapy

The prognosis of patients with recurrent, late-stage inoperable, or progressed biliary tract carcinoma (BTC) is generally poor. The goal of this clinical study is to determine the effectiveness and safety of abemaciclib in patients with late-stage or progressed BTC that has failed one line of chemotherapy.
Irina Geier at igeier@pennstatehealth.psu.edu or 717-531-4300
All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT04003896
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Histologic or cytologic evidence of advanced or metastatic biliary tract cancer including cholangiocarcinoma (intra-hepatic or extra-hepatic bile ducts), ampullary carcinoma, and gallbladder carcinoma.
Evidence of recurrent, locally advanced, or metastatic disease.
Progressed following or intolerant to one or more line of systemic therapy.
Presence of at least 1 lesion that is measurable or evaluable using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.
Adequate organ function, as evidenced by the laboratory parameters noted in Study Eligibility.
Exclusion Criteria:
Ongoing or active infection requiring systemic antibiotics.
History of previous venous thromboembolic events.
Uncontrolled hypertension despite adequate therapy (i.e., systolic blood pressure higher than 150 mm Hg or diastolic blood pressure higher than 90 mm Hg found on 2 separate occasions separated by 1 week).
Diabetes mellitus and occurrence of more than 2 episodes of ketoacidosis in the 12 months prior to the first dose of study drug.
Active second malignancy other than curatively resected basal cell carcinoma of the skin, squamous cell carcinoma of the skin, in situ carcinoma of the cervix, or other cancers with no known active disease in the 3 years prior to enrollment.
Cancer
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

Design and Evaluation of a Portable Test Bed to Measure Cognitive Workload

The purpose of the experiment is to examine the effectiveness of a portable mental workload monitor. Participants will be using a game-like computer program that tests the ability to perform multiple tasks simultaneously. The experimenter will be recording performance data as well as multiple physiological indices to include a desktop eye tracker, a simple electroencephalogram (EEG), a galvanic skin response monitor, and a heart-rate monitor. The recording devices are not intrusive and should not cause discomfort.
Snehal Dhengre at sud702@psu.edu
All
18 year(s) or older
This study is also accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Be at least 18 years of age
Understand English
Have normal or normal-corrected vision
Can use standard computer monitor, a mouse, and a game controller
Exclusion Criteria:
Have visual deficiencies where the person is unable to identify the graphical images on a computer monitor from 20” away
Require use of non-standard graphical interfaces or manipulation devices
Mental & Behavioral Health
  Email this study information to me
  Contact the study team
  Show all 1 locations

Study Locations

Hide all locations
Location
State College, PA

A Phase III Randomized Open Label Study to Compare NKTR-214 Combined with Nivolumab to the Investigator's Choice of Sunitinib or Cabozantinib in Patients with Previously Untreated Advanced Renal Cell Carcinoma (PSCI 18-122)

The purpose of the study is to compare how well the drug called NKTR-214 works when combined with the other drugs: nivolumab, sunitinib, and cabozantinib in patients with renal cell carcinoma.
Kathleen Rizzo at krizzo@pennstatehealth.psu.edu
All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT03729245
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
18 years or older
Karnofsky Performance Status of at least 70
advanced or metastatic renal carcinoma
No prior systemic therapy
No active brain metastases
Exclusion Criteria:
Use of an investigational agent or an investigational device within 28 days of randomization
autoimmune disease
History of organ or tissue transplant
Prior major surgery or radiotherapy within 14 days
Any tumor invading the major blood vessels
Cancer
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

Identity Fusion and "Vladimir's Choice": An Exploration of Costly Decision Making

This study will experimentally determine if individuals who identify more strongly with their political party are more likely to make decisions that cause discomfort and possible pain when faced with opposition and competition from individuals with opposing views. This goal will be accomplished in the laboratory via a game between individuals with opposing views that can be won by taking a shot of hot sauce.
Connor Somgynari at cjs72@psu.edu or 224-637-5504
All
18 year(s) or older
This study is NOT accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Over age 18
No food allergies
English Speaker
Exclusion Criteria:
Under age 18
Food allergies
Non-English Speakers
Food & Nutrition, Education, Mental & Behavioral Health
  Email this study information to me
  Contact the study team
  Show all 1 locations

Study Locations

Hide all locations
Location
State College, PA

The Role of Obesity on the Phenotype and Function of Human Monocytes and their Role in Atherosclerotic Risk

We are conducting a study that is comparing the distribution of monocyte subsets (i.e. classical, intermediate and non-classical monocyte) between adults aged 55-75 with obesity/metabolic syndrome and healthy controls. The participants will have one screening visit and one study visit, and both will involve a blood draw. Each visit should take an hour or less, and the compensation for this study is $10. Lab results from screening will also be provided to participants at no cost.
Ester Oh at sxo35@psu.edu or 814-867-3720
All
18 year(s) or older
This study is also accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
55-75 years old
Non-smoker
BMI between 18.5 – 35 kg/m2
Exclusion Criteria:
Systolic BP > 160 mmHg or diastolic BP > 100 mmHg
Fasting glucose > 126 mg/dL
Use of cholesterol/lipid-lowering medications
Use of anti-hypertensive medications
Use of glucose lowering medications
Infectious Diseases & Immune System, Heart & Vascular, Prevention
  Email this study information to me
  Contact the study team
  Show all 1 locations

Study Locations

Hide all locations
Location
State College, PA

Testing conflicting theories of semantics by constructing neuroinformatic networks of keywords using fMRI data

This is a brain imaging study that will examine how people mentally organize word meanings. Participants will perform a language task while in an MRI scanner, and their brain imaging data will be used to create networks of words that will be used to test conflicting theories of word meaning.
Dominick DiMercurio at dimercurio@psu.edu or 814-867-4341
All
18 year(s) or older
This study is also accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Age 18-30
Right-handed
Native speaker of English
At least a high school education
Exclusion Criteria:
History of neurogenic or psychiatric illness
Pacemaker or other metal implant
Claustrophobia
Medications that affect cognition
Language & Linguistics
  Email this study information to me
  Contact the study team
  Show all 1 locations

Study Locations

Hide all locations
Location
State College, PA

AN OPEN-LABEL STUDY TO EVALUATE THE LONG-TERM SAFETY OF DAILY ORAL BCX7353 IN SUBJECTS WITH TYPE I AND II HEREDITARY ANGIOEDEMA

This is a clinical trial to determine the effectiveness of a daily oral medication in prevention of swelling attacks in patients with Hereditary Angioedema.
Joshua Adams at jadams4@pennstatehealth.psu.edu
All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT03472040
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Type I or II HAE
Used androgen therapy for prophylaxis of HAE episodes in past 12 months
Greater than or equal 40 kg
Access to appropriate rescue medication for HAE attacks
Exclusion Criteria:
Pregnant, breastfeeding, or planned pregnancy
Prior enrollment in BCX 7353 study
Known family history of sudden cardiac death
Infectious Diseases & Immune System, Allergies
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

Site for Phase III Randomized Trial of Concurrent Chemoradiotherapy with or without Atezolizumab in Localized Muscle Invasive Bladder Cancer (Study SWOG/NRG 1806) (PSCI#19-044)

The purpose of this study is to compare the effects, good and/or bad, of chemotherapy and radiation therapy with or without the use of atezolizumab, which is used to treat bladder cancer. The combination of chemotherapy, radiation therapy and the immunotherapy atezolizumab is considered experimental. If you decide to take part in this study, you will receive combined chemotherapy and radiation therapy which is called “chemoradiotherapy” either with or without the study drug. The chemoradiotherapy you will receive is standard of care and what your doctor thinks is best. You will receive chemoradiotherapy for up to 7 weeks. If you are assigned to the group receiving study drug, you will take the drug for up to 6 months in addition the chemoradiotherapy. Your doctor will continue to follow your condition for up to 5 years after you register to the study, even though you have finished treatment in the first year. Your doctor will watch you for side effects and to see how your cancer affects you. You will have clinic visits at 3 months from the time you stop taking treatment for the first two years and then twice a year for the third year and once a year thereafter until 5 years after you register to the study.
All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT03775265
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Patients must have histologically proven, T2-T4a N0M0 urothelial carcinoma of the bladder within 70 days prior to randomization.
Patients must undergo radiological staging within 70 days prior to randomization. Imaging of chest, abdomen, and pelvis must be performed using CT or MRI. Patients must not have evidence of T4bN1-3 disease.
Patients with hydronephrosis are eligible if they have unilateral hydronephrosis and kidney function meets criteria specified.
Female patients of childbearing potential must have a serum pregnancy test prior to randomization.
Patients must be ≥ 18 years of age.
Exclusion Criteria:
Patient must not have received any systemic chemotherapy for their bladder cancer.
Patients must not have received prior treatment for muscle invasive bladder cancer including neoadjuvant chemotherapy for the current tumor.
Patients must not have a major surgical procedure within 28 days prior to randomization.
Patients must not have undergone prior allogeneic bone marrow transplantation or prior solid organ transplantation.
Patients must have adequate bone marrow function as evidenced by all of the following: ANC ≥ 1,500/microliter (mcL); platelets ≥ 100,000/mcL; Hemoglobin ≥ 9 g/dL. These results must be obtained within 28 days prior to randomization.
Cancer
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

A Phase 3, Multi-center, Open-label, Safety Study of Oral Edaravone Administered over 48 Weeks in Subjects with Amyotrophic Lateral Sclerosis (ALS)

The purpose of this study is to test if an experimental drug called edaravone is safe and well tolerated in patients with ALS. In this study, you will receive an oral form of edaravone (a liquid solution that you will swallow). This oral formulation is considered experimental, as it has not been approved to treat ALS. The IV (intravenous) form of edaravone has been approved as a treatment for ALS. The IV form was approved in 2017 by the U.S. Food and Drug Administration (“FDA”). It is known by its commercial-brand name, Radicava, and its generic name, edaravone.
All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT04165824
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Age 18-75
Forced vital capacity ≥ 70% predicted
ALS symptom onset within 3 years
Exclusion Criteria:
Undergoing treatment for cancer
Pregnancy or lactation
Hereditary fructose intolerance
Unable to take medications orally
History of hypersensitivity to edaravone
Neurology
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

Investigating the impact of food form on children’s ability to compensate for energy

This study is looking at how different apple products (apple juice, apple sauce, and apple slices) might affect children's hunger and fullness. During 5 visits to our laboratory at Penn State, children will participate in a variety of games and tasks, and will eat meals and snacks with a research assistant. Children must be between the ages of 4.5-6 years old to participate in this study.
Nicole Reigh at nar5235@psu.edu
All
Younger than 18 years old
This study is also accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Between age of 4.5-6.0 years-old
No food allergies
Exclusion Criteria:
Taking medication that can affect taste or appetite
Children's Health, Food & Nutrition
  Email this study information to me
  Contact the study team
  Show all 1 locations

Study Locations

Hide all locations
Location
State College, PA

Centre County COVID-19 Data 4 Action Study

The purpose of this research is to evaluate the extent of COVID-19 risk and perceived risk among Centre County residents and students, and how those risks evolve from the time isolation guidelines were implemented through a return to normal functioning. Participants in this research will complete an electronic survey with questions about their demographic, about their exposure to COVID-19, and about how COVID-19 has affected their health and work/education. Data from this research will be used to inform Centre County planning authorities and the Pennsylvania State University about the needs of communities, including needs for information dissemination and for potentially actionable, local interventions in response to the COVID-19 pandemic.
Susan McHale at src-ssri@psu.edu
All
18 year(s) or older
This study is also accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
At least 18 years of age.
Currently living in Centre County, PA.
Expect to continue living in Centre County, PA (through at least Sept 2020)
Capable of providing your own informed consent.
Exclusion Criteria:
No additional exclusion criteria beyond those required for inclusion.
Infectious Diseases & Immune System, Men's Health, Women's Health
  Email this study information to me
  Contact the study team

PSCI-17-085 Effect of Omega-3 Fatty Acid (EPA) and its Metabolites in Combination with Tyrosine Kinase Inhibitors (TKIs) in Chronic Myeloid Leukemia (CML) in Stable Chronic Phase

The purpose of this Phase I/II study is to evaluate the safety and efficacy of the combination of tyrosine kinase inhibitors (TKIs) and an omega-3 fatty acid (like fish oil) in patients with Chronic Myeloid Leukemia (CML).
Seema Naik at snaik@pennstatehealth.psu.edu
All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT04006847
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Confirmed diagnosis of CML ≥ 18 months from diagnosis
Current concomitant treatment with TKI therapy (Imatinib, Dasatinib, Nilotinib or Bosutinib; excluding Ponatinib)
BCR-ABL PCR at stable molecular disease (e.g. MMR stable but not CMR) or b. Hematologic remission (HR) but no MMR
Stable molecular response defined as 2 sequential BCR-ABL levels done in the same lab with less than ½ log reduction of BCR-ABL (BA)
Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) score more than or equal to 3
Exclusion Criteria:
Current malignancy requiring active treatment
Active infection requiring antibiotic treatment
Known HIV, Hepatitis B, or Hepatitis C infection
Known symptomatic congestive heart failure (CHF), unstable angina or cardiac arrhythmia
Current concomitant use of NSAIDs (including Aspirin) or COX-1; a washout period of 4 weeks prior to enrollment is permitted
Cancer
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

PEDS-PLAN – Pediatric Precision Laboratory Advanced Neuroblastoma Therapy

A study of the safety and feasibility of using molecularly guided therapy in combination with standard therapy followed by maintenance therapy with DFMO in patients with newly diagnosed high risk neuroblastoma.
Suzanne Treadway, MS, RN, CCRP at streadway@pennstatehealth.psu.edu or 717-531-3097
All
All
This study is NOT accepting healthy volunteers
NCT02559778
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
A confirmed diagnosis of neuroblastoma.
Must be 21 years of age or younger when diagnosed.
No prior systemic therapy with some exceptions.
Tumor samples will be obtained only in a non-significant risk manner and not solely for the purpose of the study.
Exclusion Criteria:
Receiving another study drug while on this study.
Female patients who are lactating are not eligible unless they agree not toe breast feed.
Children's Health, Cancer
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

Phase 3, prospective, multi-center, open label study to investigate safety, immunogenicity, and hemostatic efficacy of PEGylated Factor VIII (BAX 855) in previously untreated patients (PUPs) < 6 years with severe hemophilia A (FVIII < 1%)

Phase 3, prospective, multi-center, open label study to investigate safety, immunogenicity, and hemostatic efficacy of PEGylated Factor VIII (BAX 855) in previously untreated patients (PUPs) < 6 years with severe hemophilia A (FVIII < 1%)
All
Younger than 18 years old
This study is NOT accepting healthy volunteers
NCT02615691
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
< 6 years old at the time of screening
previously untreated with < 3 EDs to ADVATE, BAX 855 or FFP any time prior to screening
severe hemophilia A (FVIII < 1%)
Exclusion Criteria:
History or current FVIII inhibitory antibodies (≥ 0.6 BU
Diagnosis of an inherited or acquired hemostatic defect other than hemophilia A
Previously treated with cryo, PRBC, platelets or any type of FVIII concentrate other than ADVATE, BAX 855v or FFP
weight is < 5 kg
Platelet count < 100,000/mL; severe chronic hepatic dysfunction or severe renal impairment
Blood Disorders
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

Understanding Information Needs and Challenges faced by International Spouses during Adjustment

The study examines ways in which technology can be designed to provide support and services to international spouses during their adjustment to a new host environment. In particular, we would like to investigate the needs of spouse’s communities, the challenges faced by this population during adjustment, and propose design implications for developing systems and services to improve their access to social services and to promote community development and civic engagement.
Jomara Binda at jmb89@psu.edu
All
18 year(s) or older
This study is also accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Individuals who understand English
Individuals who hold a dependent (F-2/J-2) visa status
Exclusion Criteria:
Non-English speakers
Age under 18
Non-dependents (F-2/J-2) visa status
Anyone who cannot consent to participate in this study
  Email this study information to me
  Contact the study team
  Show all 1 locations

Study Locations

Hide all locations
Location
State College, PA

Attention for Neoteny Among Distractors

This is a reaction time study where participants need to detect a stimuli among distractor stimuli. This study will examine whether physical immaturity (also called neoteny) has preferential attentional mechanisms by asking participants to detect neotenous stimuli among other neotenous stimuli and non-neotenous stimuli as distractors.
Karin Machluf at kxm5600@psu.edu
All
18 year(s) or older
This study is also accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Any adult over the age of 18 years
Opens to males and females
Exclusion Criteria:
Anyone under the age of 18 years old
  Email this study information to me
  Contact the study team
  Show all 1 locations

Study Locations

Hide all locations
Location
Wilkes-Barre/Scranton Area, PA

Atrophy of Olfactory Bulb in Early-stage Parkinson’s disease

This research is being done to study the deterioration of the central olfactory system (sense of smell system) in the brains of patients diagnosed with early- stage Parkinson’s disease.
Jianli Wang at jwang2@pennstatehealth.psu.edu
All
18 year(s) or older
This study is also accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
A physician-documented parkinsonian symptom onset between the ages of 40-59 will
Patients should not have reached their 65th birthday.
Patients that have tremor, rigidity, and bradykinesia unilaterally
Exclusion Criteria:
Dementia
Autonomic dysfunction
Parkinson-plus syndrome
Postural instability
History of exposure to substances that cause parkinsonism
Neurology
  Email this study information to me
  Contact the study team
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

The Penn State Personalized Research for Innovation, Discovery, and Education (PRIDE) Program.

The Penn State Personalized Research for Innovation, Discovery, and Education (PRIDE) Program. The aims of the PRIDE Program are to: 1. Create a centralized Biorepository using extra blood obtained from a clinically-ordered blood draw, leftover biospecimens that are removed during medically indicated procedures or a saliva sample from consented participants that do not have clinically ordered blood draws or a medical procedure. 2. Construct a dynamic database of health and related data (via both manual and electronic abstraction) from consented participants. 3. Establish a mechanism for approving use of the banked biospecimens for future research.
Syndi Reed at creed@pennstatehealth.psu.edu or 855-369-3540
All
All
This study is also accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Any age
Ability of patient, child and/or parent to understand or complete the consent process
Exclusion Criteria:
Unable to understand or complete the consent process
Opted out of research studies
Men's Health, Children's Health, Women's Health
  Email this study information to me
  Contact the study team
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

User Mobility and Graph Learning in Virtual Reality

This study investigates how the interaction affects how well 3D graphs are understood and remembered in virtual reality, and how individual differences in spatial ability affect and interact with memory and understanding.
Mark Simpson at mbs278@psu.edu
All
18 year(s) or older
This study is also accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Penn State Affiliation
Exclusion Criteria:
Under age 18
Education
  Email this study information to me
  Contact the study team
  Show all 1 locations

Study Locations

Hide all locations
Location
State College, PA

Fabry Registry

The Registry is a multi-center, international, longitudinal, observational program for patients with Fabry disease that was designed to track the natural history and outcomes of patients. Data from the Registry are also used to fulfill various global regulatory commitments, to support product development/reimbursement, and for other research and non-research-related purposes. The long-term program will proceed for a minimum of 15 years.
All
All
This study is NOT accepting healthy volunteers
NCT00196742
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Have Fabry Disease
Be willing an able to provide written informed consent
Exclusion Criteria:
None
Neurology
  Email this study information to me
  Contact the study team
  See more information

Navigating virtual environments

This is a spatial cognition study that will examine how route knowledge can be acquired when exploring a virtual maze. The primary objective is to find the influence of the dynamic change of scale (low vs. high perspective) on the route representation in virtual reality.
Jiayan Zhao at juz64@psu.edu or 814-321-6982
All
18 year(s) or older
This study is also accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
At least 18 years old
Exclusion Criteria:
Younger than 18 years old
Education
  Email this study information to me
  Contact the study team
  Show all 1 locations

Study Locations

Hide all locations
Location
State College, PA

Optimizing Cord Blood and Haploidentical Aplastic Anemia Transplantation (CHAMP)

A study of the safety and effectiveness of an unrelated cord blood transplantation versus haploidentical transplantation for severe aplastic anemia.
Suzanne Treadway, MS, RN, CCRP at streadway@pennstatehealth.psu.edu or 717-531-3097
All
All
This study is NOT accepting healthy volunteers
NCT02918292
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
A diagnosis of severe aplastic anemia.
Less than 75 years of age at time of enrollment.
Failed at least one trial of immunosuppressive therapy.
Exclusion Criteria:
Inherited bone marrow failure syndromes.
Diagnosis of myelodysplastic syndrome.
Prior allogeneic stem cell transplant or solid organ transplant.
Blood Disorders, Children's Health
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

SAV005-04 "A Phase III, randomized, double-blind, placebo-controlled study of AeroVanc for the treatment of persistent methicillin-resistant Staphylococcus aureus lung infection in cystic fibrosis patients

This is a study that will examine any benefits to use cycles of inhaled vancomycin compared to placebo. Analysis of the information will include lung function results, sputum or throat culture results, questionnaires, and time to use additional antibiotics up to 48 weeks. After the first 24 weeks, all subjects can receive open label study drug for the remaining 24 weeks. There are 13 study visits spanned over 48 weeks.
Diane Kitch at dkitch@pennstatehealth.psu.edu or 717-531-5646
All
All
This study is NOT accepting healthy volunteers
NCT03181932
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
6 years old and greater
Must have Cystic Fibrosis (CF)
Positive culture for MRSA at screening
FEV1 between 30-90%
Commit to 14 visits over 12 months
Exclusion Criteria:
You may not have allergies to vancomycin
Abnormal liver or kidney function
Inability to tolerate inhaled products
Lung Disease & Asthma
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

School Choice: Factors in Making a Choice and the Impact of Economics

The purpose of this study is to communicate with decision makers (parents and guardians) to identify the processes and considerations used when seeking and determining information relative to school choice. This study will examine those factors and see if there is equality among socio economic groups.
Michelle Cook at mxc845@psu.edu
All
18 year(s) or older
This study is also accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
parent
guardian
child in elementary / middle school
live in or around a low income community
Exclusion Criteria:
no children in school
not a parent or guardian
  Email this study information to me
  Contact the study team

Athletes' Experiences in Sport

In this study, we are interested in learning about how male athletes think about and understand the experience and expression of emotion in competitive sports.
Heather MacArthur at hjm158@psu.edu
Male
18 year(s) or older
This study is NOT accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Male
Competitive athlete
Penn State student
18+ years
Exclusion Criteria:
Female
Non-athlete
Non-student
Under 18 years
Education
  Email this study information to me
  Contact the study team
  Show all 1 locations

Study Locations

Hide all locations
Location
State College, PA

The Comparability and Reproducibility of Telomere Length Measurements

This research is being done to improve our understanding of methods to measure in telomere length (TL) and how different tissues contribute to variation in determined telomere length. A telomere is a piece of DNA at the end of each chromosome, which protects the rest of the DNA from being damaged. Knowing the length of the telomeres gives us important information about your cellular age, which can be different from your actual age depending on your exposure to certain risk factors. Studies have associated shorter telomere length with a range of risk factors that predict health problems and shortened life expectancy. However, these studies have been done using different methods and different types of tissues from the body. The differences between these studies make it difficult to compare results or help people understand how to live a healthier life. Participants will be asked to complete questionnaires and provide blood, saliva, and cheek cell samples.
Megan Zinobile at muz144@psu.edu or 814-689-9017
All
18 year(s) or older
This study is also accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Participants must be adult male and female volunteers over the age of 18 at the time of enrollment.
Participants must not have an immune disease or significant medical illness.
Participants must currently be a non-smoker.
Participants cannot be pregnant or breast feeding.
Exclusion Criteria:
Individuals with an immune disease or significant medical illness will be excluded from this study.
Individuals who currently smoke will be excluded from this study.
Individuals who are currently pregnant will be excluded from this study.
  Email this study information to me
  Contact the study team
  Show all 1 locations

Study Locations

Hide all locations
Location
State College, PA